Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Sold by Two Sigma Investments LP

Two Sigma Investments LP reduced its holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 59.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 70,115 shares of the medical instruments supplier’s stock after selling 100,992 shares during the period. Two Sigma Investments LP owned about 0.18% of Harvard Bioscience worth $155,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the company. Wells Fargo & Company MN boosted its stake in shares of Harvard Bioscience by 10.6% in the first quarter. Wells Fargo & Company MN now owns 50,480 shares of the medical instruments supplier’s stock worth $111,000 after buying an additional 4,827 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Harvard Bioscience by 11.1% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 45,775 shares of the medical instruments supplier’s stock worth $101,000 after acquiring an additional 4,575 shares during the period. Globeflex Capital L P grew its holdings in Harvard Bioscience by 350.2% in the first quarter. Globeflex Capital L P now owns 103,231 shares of the medical instruments supplier’s stock valued at $228,000 after purchasing an additional 80,303 shares during the period. JPMorgan Chase & Co. lifted its holdings in Harvard Bioscience by 50.4% during the first quarter. JPMorgan Chase & Co. now owns 35,877 shares of the medical instruments supplier’s stock valued at $79,000 after purchasing an additional 12,020 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in shares of Harvard Bioscience by 1.1% in the first quarter. Acadian Asset Management LLC now owns 1,071,962 shares of the medical instruments supplier’s stock valued at $2,372,000 after acquiring an additional 11,493 shares in the last quarter. Hedge funds and other institutional investors own 63.68% of the company’s stock.

Shares of Harvard Bioscience stock opened at $3.10 on Wednesday. The company has a current ratio of 2.05, a quick ratio of 1.07 and a debt-to-equity ratio of 0.71. The company has a fifty day simple moving average of $2.79 and a 200-day simple moving average of $2.73. The stock has a market cap of $119.75 million, a price-to-earnings ratio of 34.67 and a beta of 1.53. Harvard Bioscience, Inc. has a 12-month low of $1.39 and a 12-month high of $3.50.

Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.04). Harvard Bioscience had a negative net margin of 6.11% and a positive return on equity of 4.52%. The company had revenue of $23.77 million during the quarter, compared to analyst estimates of $28.00 million.

Separately, Zacks Investment Research cut Harvard Bioscience from a “hold” rating to a “sell” rating in a research note on Tuesday, June 2nd. One investment analyst has rated the stock with a sell rating and three have assigned a hold rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $2.92.

In other news, CEO James W. Green bought 10,000 shares of Harvard Bioscience stock in a transaction dated Thursday, May 7th. The stock was bought at an average price of $2.77 per share, for a total transaction of $27,700.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Alan I. Edrick bought 20,000 shares of Harvard Bioscience stock in a transaction dated Friday, June 12th. The stock was purchased at an average price of $2.63 per share, with a total value of $52,600.00. The disclosure for this purchase can be found here. Insiders own 3.70% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.

See Also: Dead Cat Bounce

Institutional Ownership by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.